SCHEDULE: Prelude Therapeutics Insider Boosts Stake to 13.15%

Krishna Vaddi, a key insider, has reported a beneficial ownership of 13.15% in Prelude Therapeutics Inc., totaling 6,745,647 shares.

Summary

• Krishna Vaddi beneficially owns 6,745,647 shares of Prelude Therapeutics Inc. common stock.
• This represents 13.15% of the company's outstanding common stock.
• The ownership includes 5,075,889 shares directly held by Vaddi, comprising 1,999,296 voting common shares and 3,076,593 shares from options exercisable within 60 days of December 31, 2025.
• Additional shares are held through entities where Vaddi has beneficial ownership: 142,553 shares via Sidus Ventures, LLC; 423,655 shares via Dolphin City Trust; 551,776 shares via Blue Sky Trust; and 551,774 shares via Brocade Trust.
• The percentage is calculated based on 48,225,493 voting common shares outstanding as of December 31, 2025, plus Vaddi's exercisable options.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive indicator, as a substantial 13.15% beneficial ownership by a key insider like Krishna Vaddi suggests strong confidence in Prelude Therapeutics Inc.'s long-term value and strategic direction.

Positives

• Significant insider ownership by Krishna Vaddi, totaling 13.15% of Prelude Therapeutics Inc., indicates strong confidence in the company's future.
• The substantial stake, including exercisable options, aligns management's interests with those of shareholders.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that significant insider ownership, such as the 13.15% reported by Krishna Vaddi, often signals strong conviction from key personnel regarding the company's prospects, potentially differentiating it from peers with lower insider alignment.

Related Party Transactions

• Krishna Vaddi's beneficial ownership is detailed through several entities where he holds significant influence, including Sidus Ventures, LLC (manager), Dolphin City Trust (beneficiary), Blue Sky Trust (investment advisor), and Brocade Trust (investment advisor).

Stakeholder Impact

• Shareholders: Increased confidence due to significant insider ownership, potentially signaling strong belief in future performance.
• Management: Alignment of interests with shareholders through a substantial personal stake.

Key Dates

Recommendation

The significant insider ownership by Krishna Vaddi, totaling 13.15%, is a positive signal of management confidence. However, a Schedule 13G filing primarily reports ownership and does not provide comprehensive financial or operational details to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and seek further fundamental analysis before making a definitive investment decision, while acknowledging the positive signal from insider alignment.

Keywords

Prelude Therapeutics, Krishna Vaddi, Beneficial Ownership, SEC Filing, Schedule 13G, Insider Ownership, Common Stock, Voting Power, Dispositive Power